Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Celyad Oncology is a biotechnology business based in the US. Celyad Oncology stocks (CYAD.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $4.71 – an increase of 5% over the previous week. Celyad Oncology employs 95 staff and has a market cap (total outstanding stock value) of $48.8 million.
Finder's Pick for
Beginners
Finder's Pick for
Free Trades
Finder's Pick for
Commodity Stocks
Finder's Pick for
Global Trading
| Latest market close | $2.10 |
|---|---|
| 52-week range | $1.51 - $6.40 |
| 50-day moving average | $2.10 |
| 200-day moving average | $3.46 |
| Wall St. target price | $10.71 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.52 |
Note: The dollar amounts in the table below are in Canadian dollars.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the close of $2.1 from 2022-05-26
| 1 week (2022-05-20) | 5.00% |
|---|---|
| 1 month (2022-04-26) | 1.94% |
| 3 months (2022-02-25) | -34.78% |
| 6 months (2021-11-26) | -42.78% |
| 1 year (2021-05-28) | -61.96% |
|---|---|
| 2 years (2020-05-28) | -80.91% |
| 3 years (2019-05-28) | 20.2105 |
| 5 years (2017-05-26) | 39.96 |
| Gross profit TTM | $5,000 |
|---|---|
| Return on assets TTM | -26.82% |
| Return on equity TTM | -82.13% |
| Profit margin | 0% |
| Book value | $1.64 |
| Market capitalisation | $48.8 million |
TTM: trailing 12 months
We're not expecting Celyad Oncology to pay a dividend over the next 12 months.
Over the last 12 months, Celyad Oncology's shares have ranged in value from as little as $1.51 up to $6.4. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Celyad Oncology's is 1.1879. This would suggest that Celyad Oncology's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. The company's preclinical candidate includes CYAD-203, a non-gene edited allogeneic CAR-T candidate to co-express the cytokine interleukin-18 with natural killer group 2D ligands (NKG2D) for the treatment of solid tumors. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium. .
iGaming is now legal in Ontario. Find out which companies to keep an eye on with our list of 10 top online gaming stocks.
Read more…
Enjoy perks like free trades and cash rewards when you open a stock trading account with these online brokers.
Read more…
Here’s what you need to know about investing in the propane industry, including 3 popular propane stocks to watch.
Read more…Steps to owning and managing BGXX stock, with 24-hour and historical pricing before you buy.
Learn more about apps like Wealthsimple to find the best trading platform for your unique set of needs.
iGaming is now legal in Ontario. Find out which companies to keep an eye on with our list of 10 top online gaming stocks.
Steps to owning and managing ENT stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing KAMBI stock, with 24-hour and historical pricing before you buy.
Enjoy perks like free trades and cash rewards when you open a stock trading account with these online brokers.
Steps to owning and managing RSI stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing PBTHF stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing Hanover Bancorp stocks, with 24-hour and historical pricing before you buy.
Everything we know about the PrimeBlock IPO, plus information on how to buy in.